(Q35331699)

English

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

0 references

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

postmenopausal osteoporosis

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

organic compound, having C-P covalent bound

1 reference

12 November 2019

bone density conservation agents

1 reference

16 July 2021

systematic review

1 reference

based on heuristic

inferred from title

author name string

Young Ho Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Gwan Gyu Song

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 September 2011

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

The Korean journal of internal medicine

5 references

Europe PubMed Central

PubMed publication ID

7 August 2017

13 March 2019

24 March 2019

12 November 2019

16 July 2021

26

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

340-347

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

4 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

24 March 2019

Europe PubMed Central

12 November 2019

Europe PubMed Central

16 July 2021

on focus list of Wikimedia project

0 references

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Ibandronate: a review of its use in the management of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Ibandronate: a clinical pharmacological and pharmacokinetic update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

12 July 2018

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Compliance with drug therapies for the treatment and prevention of osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Compliance with pharmacologic therapy for osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192207

26 September 2018

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22016595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analyses of randomised controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22016595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3904/KJIM.2011.26.3.340

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35331699&oldid=1970740983"